26179-59-9

Upstream product

• 461-82-5 4-(trifluoromethoxy)aniline 
• 1493-27-2 ortho-nitrofluorobenzene 
• 26179-57-7 o-Nitrophenyl-N-(p-trifluoromethoxyphenyl)-benzimidate 
• 26179-58-8 N-Benzoyl-2-nitro-4'-trifluoromethoxydiphenylamin 

Downstream Products

• 1353734-12-9 5-(4-trifluoromethoxyphenyl)-3-(4-methoxycyclohexyl)imino-2-(2-methoxy-3-pyridyl)amino-3,5-dihydrophenazine 
• 1353734-14-1 5-(4-trifluoromethoxyphenyl)-3-(4-tetrahydropyranyl)imino-2-(2-methoxy-3-pyridyl)amino-3,5-dihydrophenazine 
• 1353734-07-2 5-(4-trifluoromethoxyphenyl)-3-isopropylimino-2-(2-methoxy-3-pyridyl)amino-3,5-dihydrophenazine 
• 1353733-94-4 5-(4-trifluoromethoxyphenyl)-3-isopropylimino-2-(3-pyridyl)amino-3,5-dihydrophenazine 
• 1353733-99-9 5-(4-trifluoromethoxyphenyl)-3-(2-morpholinoethyl)imino-2-(3-pyridyl)amino-3,5-dihydrophenazine 
• 1353733-95-5 5-(4-trifluoromethoxyphenyl)-3-(N-isobutyl-4-piperidyl)imino-2-(3-pyridyl)amino-3,5-dihydrophenazine 
• 1353733-97-7 5-(4-trifluoromethoxyphenyl)-3-(N-methyl-4-piperidyl)imino-2-(3-pyridyl)amino-3,5-dihydrophenazine 
• 1353734-03-8 5-(4-trifluoromethoxyphenyl)-3-(4-methoxycyclohexyl)imino-2-(3-pyridyl)amino-3,5-dihydrophenazine 
• 1353734-01-6 5-(4-trifluoromethoxyphenyl)-3-(4-tetrahydropyranyl)imino-2-(3-pyridyl)amino-3,5-dihydrophenazine 

Relevant academic research and scientific papers

Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis

Clofazimine (CFZ), a member of the riminophenazine class, has been studied in clinical trials for the treatment of multidrug-resistant tuberculosis (MDR-TB). CFZ has several side effects which can be attributed to its extremely high lipophilicity. A series of novel riminophenazine analogues bearing a C-2 pyridyl substituent was designed and synthesized with the goal of maintaining potent activity against Mycobacterium tuberculosis (M. tuberculosis) while improving upon its safety profile by lowering the lipophilicity. All compounds were evaluated for their in vitro activity and cytotoxicity. The results demonstrated that many new compounds had potent activity against M. tuberculosis with MICs of less than 0.03 μg/mL and low cytotoxicity with IC50 values greater than 64 μg/mL. Some compounds were tested for in vivo efficacy against MDR-TB in an experimental mouse infection model. Two compounds demonstrated equivalent or better efficacy than CFZ in this model with significantly reduced skin discoloration potential.

Preparation method of pyrifazimine

The invention provides a preparation method of pyrifazimine. The preparation method includes the steps of firstly, using 2-fluoronitrobenzene and 4-trifluoromethoxyaniline as the initial raw materialsto perform substitution reaction to obtain a compound II; secondly, subjecting the compound II to reduction to obtain a compound III, and allowing the compound III to have reaction with 1,5-difluoro-2,4-dinitrobenzene to prepare a compound IV; thirdly, subjecting the compound IV and 2-methoxy-3-aminopyridine to substitution reaction to obtain a compound V; fourthly, subjecting the compound V to reduction to obtain a compound VI, and performing cyclization reaction to generate a compound VII; fifthly, allowing the compound VII to have reaction with trans-4-methoxycyclohexylamine under the catalysis of acid to obtain the pyrifazimine. The preparation method is simple to operate, mild in reaction conditions, high in yield and suitable for industrial production.

Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors

A series of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety were synthesized and evaluated for their c-Met kinase inhibitory activity and antiproliferative activity against five cancer cell lines (HT-29, H460, A549, MKN-45 and U87MG) in vitro. Most of the compounds exhibited moderate-to-significant cytotoxicity as compared with foretinib. The most promising compound 41 (with c-Met IC50 value of 0.90?nM) showed remarkable cytotoxicity against HT-29, H460, A549, MKN-45 and U87MG cell lines with IC50 values of 0.06?μM, 0.05?μM, 0.18?μM, 0.023?μM and 0.66?μM, respectively, and thus it was 1.22- to 3.50-fold more potent than foretinib. Their preliminary structure-activity relationships (SARs) studies indicate that electron-withdrawing groups on the terminal phenyl rings are beneficial for improving the antitumor activity.

PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS

HPV inhibitors with formula (I) where G1 represents a hydrocarbonated bond or chain possibly substituted by one or two alkyl groups, G2 represents a group (see formula Ia+Ib) or R represents a hydrogen, an alkyl, halogenoalkyl, or a prodrug radical such as carbamate, acetyl or dialkylaminomethyl, G represents a bond or a hydrocarbonated chain possibly substituted by one or two alkyls, W represents an oxygen or sulphur, R1 and R2 each represent a group chosen from among hydrogen, halogen, hydroxyl, thio, alkoxy, halogenoalkoxy, alkylthio, halogenoalkylthio, amino, monoalkylamino, dialkylamino, cycloalkyl, alkyl or halogenoalkyl, R3 represents an acid or a prodrug radical of the acid function or a bioisostere of the acid function, A represents an aryl, cycloalkyl, cycloalkenyl or a heterocycle, each possibly substituted, and B represents an aryl or a heterocycle with 6 chains, each possibly substituted, and pharmaceutically acceptable salts.